Clinical Trial

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients. Participants will be treated with low-dose JYP0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose JYP0061. Efficacy and safety evaluations will be conducted according to the protocol.
Trial Details
NCT Number NCT06697535
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Neuromyelitis Optica Spectrum Disorders
Enrollment 35 participants
Start Date 2023-05-24
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-20